RayzeBio Inc.

Cancer drug developer $RYZB, which only went public in September of this year is up 100% after being acquired by Bristol Myers Squibb ($BMY) for $4.1 billion

Share this article:

About the Author:

RayzeBio Inc.

Joey Ramson

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup